EIN Presswire reported that POP Biotechnologies, co-founded by Jonathan Lovell, will collaborate with UB to pursue the development of a unique vaccine approach against seasonal influenza.
Alevriadou is recognized for her pioneering cellular and molecular work on vascular endothelial mechanotransduction and mitochondrial redox signaling, and for her service to the society.
WKBW-TV quoted Jonathan Lovell in an article about his work developing a vaccine for Alzheimer’s disease. The treatment was effective in mice and the team is moving to gain FDA approval for human testing.
The Buffalo News reported that UB’s Center for Advanced Technology in Big Data and Health Sciences has awarded grants to nine health sciences projects by eight companies, including projects led by Jonathan Lovell and Jun Xia.
